Anixa Biosciences, Inc. is a clinical stage biotechnology company focused on the treatment and prevention of cancer.
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
We are developing a revolutionary vaccine technology focused on treating and preventing multiple forms of breast cancer.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine against ovarian cancer.
Lung, Colon, & Prostate Cancer Vaccines
We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.